Pharmacology & Therapeutics

Article	Citations
Tumor microenvironment as a therapeutic target in cancer	628
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections	347
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms	263
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development	228
Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?	212
Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders	212
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients	208
The birth of artemisinin	159
The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species	158
Resolution of inflammation: An organizing principle in biology and medicine	143
Advances in pathogenesis and therapeutic strategies for osteoporosis	137
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions	136
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression	135
TRPC channels: Structure, function, regulation and recent advances in small molecular probes	128
Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans	109
Therapeutic targets in lung tissue remodelling and fibrosis	109
Targeting autophagy in ischemic stroke: From molecular mechanisms to clinical therapeutics	108
Programming inflammatory cell death for therapy	107
Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective	105
Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment	103
The strategies and techniques of drug discovery from natural products	100
Carcinogenesis: Failure of resolution of inflammation?	99
Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential	97
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint	96
Therapeutic potential of resveratrol against emerging respiratory viral infections	95

Physiologically-based pharmacokinetic models for children: Starting to reach maturation?	90
Traditional application and modern pharmacological research of Artemisia annua L.	89
Drug repurposing for COVID-19: Approaches, challenges and promising candidates	87
Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases	87
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	85
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders	83
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders	81
Targeting the NLRP3 inflammasome in cardiovascular diseases	80
The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy	79
Role of the ERO1-PDI interaction in oxidative protein folding and disease	79
Chinmedomics, a new strategy for evaluating the therapeutic efficacy of herbal medicines	78
Role of inflammatory chemokines in hypertension	76
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms	76
Evidence-based pharmacological treatment options for ADHD in children and adolescents	76
Bile acid metabolism and signaling, the microbiota, and metabolic disease	76
Polyphenols and neuroprotection: Therapeutic implications for cognitive decline	73
Biased GPCR signaling: Possible mechanisms and inherent limitations	71
Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma	71
Kynurenine emerges from the shadows – Current knowledge on its fate and function	71
Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies	69
Current developments of targeting the p53 signaling pathway for cancer treatment	68
The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention	68
A decade of cell death studies: Breathing new life into necroptosis	68
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications	67
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy	67
Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis	65
The Role of non-coding RNAs in colorectal cancer, with a focus on its autophagy	65
Updates on community acquired pneumonia management in the ICU	65
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options	62
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges	62
Circular RNAs are a novel type of non-coding RNAs in ROS regulation, cardiovascular metabolic inflammations and cancers	62
Tumor organoid models in precision medicine and investigating cancer-stromal interactions	62
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases	61
Metal-dependent Ser/Thr protein phosphatase PPM family: Evolution, structures, diseases and inhibitors	61
Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain	60
Stepping forward in antibody-drug conjugate development	60
Sirtuins' control of autophagy and mitophagy in cancer	59
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	58
Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences	58
Targeting post-translational histone modifying enzymes in glioblastoma	57
G-quadruplex-based aptamers targeting human thrombin: Discovery, chemical modifications and antithrombotic effects	56
A deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer	54
Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy	54
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials	54
Molecular mechanisms of ferroptosis and their involvement in brain diseases	54
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights	52
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders	52
Advances in the research on the targets of anti-malaria actions of artemisinin	51
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	51
Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing	51

Immune activities of polysaccharides isolated from Lycium barbarum L. What do we know so far?	51
Effects of local anesthetics on cancer cells	51
Particulate matter air pollutants and cardiovascular disease: Strategies for intervention	51
Myeloperoxidase: Mechanisms, reactions and inhibition as a therapeutic strategy in inflammatory diseases	51
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	50
TGFβ-Directed Therapeutics: 2020	50
New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma	49
FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention	49
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19	49
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	48
Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system	48
Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy	47
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance	47
Genotoxic therapy and resistance mechanism in gliomas	47
GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors	47
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system	47
Metabolomics, metabolic flux analysis and cancer pharmacology	47
Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy	46
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	46
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target	46
FGFR4: A promising therapeutic target for breast cancer and other solid tumors	45
Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications	45
Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases	45
Treatment of overdose in the synthetic opioid era	45
Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?	45
Antimicrobial peptides – Unleashing their therapeutic potential using nanotechnology	44
Toxicology of flavoring- and cannabis-containing e-liquids used in electronic delivery systems	44
Clinical therapies and nano drug delivery systems for urinary bladder cancer	44
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	44
Extracellular vesicles in cancer diagnostics and therapeutics	42
Molecular imaging of inflammation - Current and emerging technologies for diagnosis and treatment	42
Current state and future perspective of cardiovascular medicines derived from natural products	42
Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination	42
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	42
An overview on anti-tubulin agents for the treatment of lymphoma patients	42
Cyclodextrins: Potential therapeutics against atherosclerosis	41
Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer	41
Targeting BET bromodomain proteins in cancer: The example of lymphomas	41
NF-κB signaling promotes castration-resistant prostate cancer initiation and progression	41
Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan	41
Targeting the crosstalk between canonical Wnt/β-catenin and inflammatory signaling cascades: A novel strategy for cancer prevention and therapy	41
New perspectives on the role of Drp1 isoforms in regulating mitochondrial pathophysiology	41
Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention	40
Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis	40
SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin	39
The role of CD71+ erythroid cells in the regulation of the immune response	39
Novel strategies exploiting interleukin-12 in cancer immunotherapy	39
Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds	39
Pulmonary arterial hypertension specific therapy: The old and the new	38
Induction of programmed necrosis: A novel anti-cancer strategy for natural compounds	38
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities	38
Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside	38
Signal transduction in primary cilia – analyzing and manipulating GPCR and second messenger signaling	38
Myeloperoxidase: A versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease	38
The regulation of PKA signaling in obesity and in the maintenance of metabolic health	37
Recent advances in genome editing of stem cells for drug discovery and therapeutic application	37
In cancer, all roads lead to NADPH	37
Enhancing autophagy in Alzheimer's disease through drug repositioning	36
TSH/IGF1 receptor crosstalk: Mechanism and clinical implications	36
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	36
Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments	36
Long noncoding RNA loss in immune suppression in cancer	35
Dietary nutrition for neurological disease therapy: Current status and future directions	35
Rational targeting of immunosuppressive neutrophils in cancer	35
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	35
Cyclooxygenases and the cardiovascular system	35
Glycoprotein VI - novel target in antiplatelet medication	35
Functional hydrogels as therapeutic tools for spinal cord injury: New perspectives on immunopharmacological interventions	35
Medulloblastoma: Molecular understanding, treatment evolution, and new developments	35
Therapeutic potential of the target on NLRP3 inflammasome in multiple sclerosis	34
TSLP as druggable target – a silver-lining for atopic diseases?	34
Keep an eye on adenosine: Its role in retinal inflammation	34
The roles of non-coding RNAs in vascular calcification and opportunities as therapeutic targets	34
Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges	34
Inflammation in kidney repair: Mechanism and therapeutic potential	34
Physiology and pharmacology of amyloid precursor protein	34
Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development	34
Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells	34
Resolving inflammation by TAM receptor activation	34
Mitochondrial K+ channels and their implications for disease mechanisms	33

The emerging role of leukemia inhibitory factor in cancer and therapy	33
The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies	33
Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach	33
Pharmacological targets of metabolism in disease: Opportunities from macrophages	33
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders	32
The chemistry and toxicology of vaping	32
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality	32
Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets	32
Nanomedicine: Photo-activated nanostructured titanium dioxide, as a promising anticancer agent	32
Animal models of fibromyalgia: What is the best choice?	31
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	31
CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design	31
Natural products targeting mitochondria: emerging therapeutics for age-associated neurological disorders	31
Gulf War Illness: Mechanisms Underlying Brain Dysfunction and Promising Therapeutic Strategies	31
Cannabinoids as therapeutics for PTSD	31
Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits	31
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping	31
Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications	30
Branched and linear fatty acid esters of hydroxy fatty acids (FAHFA) relevant to human health	30
The gut microbiome and efficacy of cancer immunotherapy	30
Do antidepressants promote neurogenesis in adult hippocampus? A systematic review and meta-analysis on naive rodents	30
Anti-cancer activity of sustained release capsaicin formulations	30
TLR4 biased small molecule modulators	30
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions	29
Signal transducer and activator of transcription 3 signaling in tumor immune evasion	29
The Multiple Roles of the IAP Super-family in cancer	29
What's Love Got to do with it: Role of oxytocin in trauma, attachment and resilience	29
The pathophysiological function of non-gastrointestinal farnesoid X receptor	29
Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response	29
Statins and autoimmunity: State-of-the-art	29
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor	29
The translational values of TRIM family in pan-cancers: From functions and mechanisms to clinics	28
Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy	28
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors	28
Resistance looms for KRAS G12C inhibitors and rational tackling strategies	28
NRF2 in human neoplasm: Cancer biology and potential therapeutic target	28
Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know	28
Transcription factor GLIS3: Critical roles in thyroid hormone biosynthesis, hypothyroidism, pancreatic beta cells and diabetes	28
The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance	28
Exploring the proteasome system: A novel concept of proteasome inhibition and regulation	28
Public health risks associated with chronic, low-level domoic acid exposure: A review of the evidence	28
Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor	27
Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus	27
Statins in the treatment of depression: Hype or hope?	27
A BAG's life: Every connection matters in cancer	27
Melanosome transport and regulation in development and disease	27
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy	27
An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers	27
A natural products solution to diabetic nephropathy therapy	27
Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases	27
Therapeutic potential of sulfur-containing natural products in inflammatory diseases	27
Ion channels as effectors of cyclic nucleotide pathways: Functional relevance for arterial tone regulation	26
A natural product solution to aging and aging-associated diseases	26
Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer	26
Nitrite and myocardial ischaemia reperfusion injury. Where are we now?	26
The role of hypoxia-inducible factors in cardiovascular diseases	26
Targeting neurotrophic factors: Novel approaches to musculoskeletal pain	26
The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI)	25
Efficacy and mechanism of actions of natural antimicrobial drugs	25
Cannabinoids in the descending pain modulatory circuit: Role in inflammation	25
Lipopolysaccharide lipid A: A promising molecule for new immunity-based therapies and antibiotics	25
Target identification and validation of natural products with label-free methodology: A critical review from 2005 to 2020	25
Targeting defective pulmonary innate immunity – A new therapeutic option?	25
Novel insights into RIPK1 as a promising target for future Alzheimer’s disease treatment	25
The antidepressant actions of ketamine and its enantiomers	25
Recent advances in clinical trials targeting the kynurenine pathway	24
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors	24
Approaches to improve intestinal and transmucosal absorption of peptide and protein drugs	24
Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials	24
Vitamin A in health care: Suppression of growth and induction of differentiation in cancer cells by vitamin A and its derivatives and their mechanisms of action	23
Transport function, regulation, and biology of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4)	23
Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy	23
The IL-18/IL-18R1 signalling axis: Diagnostic and therapeutic potential in hypertension and chronic kidney disease	23
Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception	23
Novel molecular targets in gastric adenocarcinoma	22
Addiction and the kynurenine pathway: A new dancing couple?	22
Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation	22
Recent advances in studies of SLCO2A1 as a key regulator of the delivery of prostaglandins to their sites of action	22
Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities	22
Clinical advances in oncolytic virotherapy for pediatric brain tumors	22
Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in tre	22
The contribution of altered neuronal autophagy to neurodegeneration	22
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets	22
Nicotine’ actions on energy balance: Friend or foe?	22
Pharmacological prevention of intimal hyperplasia: A state-of-the-art review	22
The evolving obesity challenge: targeting the vagus nerve and the inflammatory reflex in the response	22
Molecular mechanisms and cardiovascular implications of cancer therapy-induced senescence	22
Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases	22
RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target	22
PET imaging of immune checkpoint proteins in oncology	21
Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine	21
Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities	21
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment	21
Cocaine use disorder: A look at metabotropic glutamate receptors and glutamate transporters	21
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	21